It was the ethical questions that were new. Is GH not a wise use of finite healthcare resources, or is the physician’s primary responsibility to the patient? If GH is given to most extremely short children to make them taller, will the definition of “extremely short” simply rise, negating the expected social benefit? If GH is given to short children whose parents can afford it, will shortness become a permanent mark of lower social origins? More of these issues are outlined in the ethics section. Whole meetings were devoted to these questions; pediatric endocrinology had become a specialty with its own bioethics issues.
Clinical field studies were conducted in 297 dogs of different breeds undergoing orthopedic or soft tissue surgery. Dogs were administered 2 mg/lb of carprofen two hours prior to surgery then once daily, as needed for 2 days (soft tissue surgery) or 3 days (orthopedic surgery). Carprofen was well tolerated when used in conjunction with a variety of anesthetic-related drugs. The type and severity of abnormal health observations in carprofen-and placebo-treated animals were approximately equal and few in number (see Adverse Reactions ). The most frequent abnormal health observation was vomiting and was observed at approximately the same frequency in carprofen- and placebo- treated animals. Changes in clinicopathologic indices of hematopoetic, renal, hepatic, and clotting function were not clinically significant. The mean post-treatment serum ALT values were IU and IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. The mean post-treatment AST values were IU less for dogs receiving carprofen and IU greater for dogs receiving placebo.
In normal tissue, DIM (300nM) can activate the ATM genetic repair pathway in response to irradiation damage in a manner dependent on BRCA1 (one of its targets  ) without increasing survival of breast cancer cells (MDA-MB-231  ); there are known alterations in this pathway in some breast cancers where BRCA1 is reduced while ATM itself seems to be hyperactive, and oral supplementation of 300mg DIM has been noted to increase BRCA1 mRNA levels after 4-6 weeks supplementation (measured in white blood cells) in women who had a low activity mutation.